TOKYO, Mar 23 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) signed a licensing agreement with Astellas Pharma for its therapeutic antibody PFKR.
Under the deal, Chiome granted Astellas worldwide exclusive rights to develop, manufacture, and sell PFKR, including sublicensing rights. Initial payment was ¥200 million, with milestone payments and royalties based on future sales up to approximately ¥24.80 billion. In the fiscal year ending December 2025, Chiome reported revenue of ¥593 million, surpassing the forecasted ¥500 million.
Revenue growth was driven by a joint development contract with Alfresa Holdings. Chiome's pipeline includes projects such as CBA1,205 and CBA1,535, targeting clinical phase trials for various cancers. Looking ahead, Chiome plans significant investments in ongoing projects like CBA__NUM_31__ and PFKR, aiming to maximize product value through data acquisition and strategic partnerships.
Additionally, the company continues to explore new opportunities in research collaborations and biologics development to enhance its portfolio and profitability.
🟡 Confidence: Standard AI-translated content.